Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double Blind- Randomized, Placebo-controlled Study of Two Doses of Capravirine (AG1549) in Combination With Viracept and Two Nucleoside Reverse Transcriptase Inhibitors in HIV Infected Patients Who Failed an Initial Nonnucleoside Reverse Transcriptase Inhibitor Containing Regimen

NCT00051844 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00051844
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00051844 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double Blind- Randomized, Placebo-controlled Study of Two Doses of Capravirine (AG1549) in Combination With Viracept and Two Nucleoside Reverse Transcriptase Inhibitors in HIV Infected Patients Who Failed an Initial Nonnucleoside Reverse Transcriptase Inhibitor Containing Regimen
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2002
Completion date
November 30, 2004
Enrollment
179 (actual)
Sites
52

Conditions

As the registry lists them; a condition with its own page is linked.

human immunodeficiency virus